Advertisement
Screener

INVIVYD, INC. (IVVD) Purchase Obligation

2.8 / 5 stars · 68/120 Roast Me

INVIVYD, INC. Purchase Obligation

INVIVYD, INC. (IVVD) had Purchase Obligation of $13.25 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Notes › Purchase Obligation, Fiscal Year Maturity

us-gaap:PurchaseObligation · last filed 2026-08-13

  • 2026-06-30: Purchase Obligation $13.25M.
  • 2026-03-31: Purchase Obligation $13.65M.
  • 2025-12-31: Purchase Obligation $2.64M.
  • 2025-09-30: Purchase Obligation $2.86M.
Period endPurchase Obligation
2026-06-30$13.25M
10-Q · filed 2026-08-13
2026-03-31$13.65M
10-Q · filed 2026-05-14
2025-12-31$2.64M
10-K · filed 2026-03-05
2025-09-30$2.86M
10-Q · filed 2025-11-06
2025-06-30$3.19M
10-Q · filed 2025-08-14
2025-03-31$910.00K
10-Q · filed 2025-05-15
2024-12-31$1.33M
10-K · filed 2025-03-20
2024-09-30$1.68M
10-Q · filed 2024-11-14
2024-06-30$688.00K
10-Q · filed 2024-08-14
2024-03-31$1.84M
10-Q · filed 2024-05-09
2023-12-31$2.28M
10-K · filed 2024-03-28
2023-09-30$2.71M
10-Q · filed 2023-11-09
2023-06-30$3.15M
10-Q · filed 2023-08-10
2023-03-31$3.58M
10-Q · filed 2023-05-11
2022-12-31$4.01M
8-K · filed 2024-02-09
2022-04-30$159.40M
8-K · filed 2024-02-09
2021-12-31$139.54M
10-K · filed 2022-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49